Valneva’s (VALN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Valneva (NASDAQ:VALN) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $18.00 price target on the stock.

Valneva Stock Performance

VALN stock opened at $5.78 on Friday. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $469.68 million, a price-to-earnings ratio of -44.46 and a beta of 1.93. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The firm has a 50 day moving average of $4.35 and a two-hundred day moving average of $5.68.

Institutional Trading of Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA acquired a new position in shares of Valneva SE (NASDAQ:VALN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.